Pharmaceutical GMP Readiness in Brazil
Brazil's ANVISA (Agência Nacional de Vigilância Sanitária) regulates medicines under Law 6.360/1976 and a series of Resolutions of the Collegiate Board (RDCs).
In Short
- ANVISA is the federal authority.
- Marketing requires a registration (registro sanitário) held by a Brazilian legal entity.
- SNCM requires unique-identifier serialization (GTIN + serial + batch + expiry) on all human medicines, with reporting through ANVISA's national hub at each…
The current GMP regulation is RDC 658/2022 (in force from 2022, replacing RDC 301/2019), aligned with PIC/S GMP — Brazil became a PIC/S member in 2021. Every manufacturing site (domestic or foreign) supplying Brazil needs a Certificate of Good Manufacturing Practices (CBPF) from ANVISA. Serialization is mandatory under the Sistema Nacional de Controle de Medicamentos (SNCM). This guide covers the Brazil-specific layer.
Regulator and Legal Basis
ANVISA is the federal authority. RDC 658/2022 sets GMP for human medicines and biologicals; RDC 654/2022 covers active ingredients (DIFAs); RDC 665/2022 covers IMPs.
More on regulator and Legal Basis
Brazil joined PIC/S in 2021 — RDC 658 is essentially PE 009 with Brazilian terminology. ANVISA inspects and issues CBPFs on a 2-year cycle.
Registration and CBPF
Marketing requires a registration (registro sanitário) held by a Brazilian legal entity. Each manufacturing site listed on the registration needs a current CBPF; ANVISA inspects foreign sites on a queue (historically 18–36 months) — this is a primary bottleneck for new entrants.
More on registration and CBPF
CBPF is granted by product class (sterile, non-sterile, biologicals, etc.).
SNCM Serialization and Dossier Language
SNCM requires unique-identifier serialization (GTIN + serial + batch + expiry) on all human medicines, with reporting through ANVISA's national hub at each supply-chain event. Dossiers and labelling must be in Portuguese; technical content may be supported by English data but key sections need certified translation.
Inspection Style and Common Findings
ANVISA inspections follow PIC/S classification (critical/major/other). Brazilian inspectors are detail-driven; common findings: stability program adequacy for tropical zones (Zone IVb), data integrity, supplier qualification of imported APIs (including DIFAs registration), and Annex 1 contamination control.
A 90–180 day Brazil readiness path
- Days 0–30
identify the Brazilian registration holder and map products to CBPF scope.
- Days 31–90
align documentation to RDC 658/2022, complete Portuguese labelling and IFU, and verify SNCM serialization onboarding.
- Days 91–180
submit CBPF inspection request; meanwhile run mock inspection and close ICH Q1A stability gaps for Zone IVb.
Questions
How long is the CBPF inspection queue?
Historically 18–36 months for foreign sites, though it has shortened recently and PIC/S reliance is being expanded. Plan early — CBPF is the long pole for Brazil market entry.
What is a DIFA?
Dossiê de Insumo Farmacêutico Ativo — an API/active master file registered with ANVISA. Each registered medicinal product must reference an approved DIFA for each active ingredient.
What stability zone applies to Brazil?
Zone IVb (30 °C / 75% RH) for most of the country. Stability programs designed only for Zone II (25 °C / 60% RH) are a common reason for delays.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
Keep reading
Global Pharmaceutical GMP Readiness: Principles That Travel- Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP
Canada Drug GMP Readiness: Food and Drug Regulations Part C, Division 2
China Pharmaceutical GMP Readiness: NMPA and China GMP
EU GMP Guide: EudraLex Volume 4 Chapters, Annexes and Who Decides
GCC Pharmaceutical GMP Readiness: Saudi SFDA and UAE